News

This new analysis indirectly compares the clinical efficacy of risankizumab and icotrokinra in adults living with moderate-to-severe plaque psoriasis.

This interview highlights both key findings and the significance of the POSITIVE trial for clinicians and for individuals with psoriasis.

Catch up on the latest in hepatology, from bulevirtide’s FDA approval for hepatitis delta to expert perspectives on new and emerging therapies in PBC, PSC, and MASLD.

Here are 7 of the biggest nephrology stories from Q2 of 2026!

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

Catch up on phase 3 data for tulisokibart and obefazimod, expert perspective on linaclotide's expanded FDA approval, and more.

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

This review of June 2026 headlines covers the most notable stories in dermatology, including FDA news, new data, and podcast updates.

June 2026 pulmonology news includes conversations with experts at the ATS and APAPP conferences, and cytisinicline's CRL.

This interview segment from SDPA highlights insights on hormonal impacts on dermatology as well as other key highlights from sessions at the meeting.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Andrew Bzowyckyj, PharmD, explains the transition to the 2021 CKD-EPI equation and its implications for medication decisions.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

Exagamglogene autotemcel (Casgevy) is now the first CRISPR-based gene-editing therapy to reach this age group in either condition.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

A roundup of key FDA approvals, pipeline advances, and updated guidelines shaping allergy and HAE care in the first half of 2026.

This interview at the SDPA Summer Conference highlights key myths and how to address them as a clinician in dermatology.

Catch up on the nephrology headlines you missed in June 2026.

A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.

Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.

This FDA News Month in Review provides a round-up of regulatory decisions from June 2026.

FDA epinephrine updates, phase 3 HAE data on lonvo-z, and new food allergy prevention research from April through June 2026.

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

June 2026 pulmonology news includes conversations with experts at the ATS and APAPP conferences, and cytisinicline's CRL.